Alex Waterhölter

Alex Waterhölter

Auto-generated profile, based on publicly available information

Alex Waterhölter

Institute of Epidemiology and Prevention, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
NSNikhat Shaikh
Nikhat Shaikh
AWAlex Waterhölter
Alex Waterhölter
AGAnn-Christin Gnirck
Ann-Christin Gnirck
MBMartina Becker
Martina Becker
VAVirginia Adamiak
Virginia Adamiak
JTJan-Eric Turner
Jan-Eric Turner
Adaptation of immune cells to tissue-specific microenvironments is a crucial process in homeostasis and inflammation. Here, we show that murine effector type 2 innate lymphoid cells (ILC2s) from various organs are equally effective in repopulating ILC2 niches in other anatomical locations where they adapt tissue-specific phenotypes of target organs. Single-cell transcriptomics of ILC2 populations revealed upregulation of retinoic acid (RA) signaling in ILC2s during adaptation to the small intestinal microenvironment, and RA signaling mediated reprogramming of kidney effector ILC2s toward the small intestinal phenotype in vitro and in vivo. Inhibition of intestinal ILC2 adaptation by blocking RA signaling impaired worm expulsion during Strongyloides ratti infection, indicating functional importance of ILC2 tissue imprinting. In conclusion, this study highlights that effector ILC2s retain the ability to adapt to changing tissue-specific microenvironments, enabling them to exert tissue-specific functions, such as promoting control of intestinal helminth infections.

9 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AWAlex Waterhölter
Alex Waterhölter
RSRebecca Scholz
Rebecca Scholz
ATAndreas Tsouris
Andreas Tsouris
FCFrancesca Cuomo
Francesca Cuomo
MAMojca Adlesic
Mojca Adlesic
IFIan J. Frew
Ian J. Frew
Background: Loss of the Y chromosome (LOY) is the most frequent somatic alteration in male cancers and has recently been linked to immune evasion, metabolic reprogramming and prognosis. Because the Y chromosome encodes transcriptional and epigenetic regulators, such as UTY and KDM5D, LOY is assumed to act through dysregulation of autosomal gene expression. We asked whether LOY produces a transcriptional signature in clear cell renal cell carcinoma (ccRCC), where about 40% of male tumors lose the Y chromosome. Methods: Here, we inferred Y chromosome status from RNA-sequencing of male ccRCC in TCGA-KIRC (n = 289) and CPTAC-ccRCC (n = 114), in 32 tumors from an autochthonous Vhl/Trp53/Rb1-deficient mouse model, and in five isogenic Y-deficient and five Y-retaining clones of the 786-O cell line. Differential expression was tested with Wilcoxon rank-sum tests on age- and purity-adjusted residuals combined by Stouffer meta-analysis (human cohorts) or with DESeq2 (mouse, cell clones), followed by gene set enrichment analysis. Pseudoautosomal genes, present on both sex chromosomes, served as internal controls for a halving of gene dosage. Results: In all three settings, transcriptional changes were confined to the expected dosage effects of male-specific Y and pseudoautosomal genes. No autosomal gene reached the significance level of the non-compensated pseudoautosomal genes in human ccRCC, 14 autosomal genes were altered in the mouse model and 40 in the isogenic 786-O clones, none shared across settings. Gene set enrichment analysis revealed a modest, reproducible upregulation of cell division, ribosome biogenesis and DNA repair pathways shared between human and murine ccRCC. A meta-analysis across 27 male TCGA cancer entities (1,710 LOY, 2,988 Y-retaining tumors) recovered the same pattern with no autosomal gene showing a consistent large effect, and the same cell division, ribosome biogenesis and DNA repair pathways were modestly upregulated. Cancer/testis antigen expression was elevated in LOY tumors of several entities, most notably stomach adenocarcinoma, but not ccRCC. Conclusions: Beyond direct gene dosage, LOY leaves the transcriptome of ccRCC, and of most other cancer entities, essentially unchanged. Y-encoded genes are therefore unlikely to drive cancer through direct transcriptional regulation of autosomal genes, directing attention to non-transcriptional effects of LOY.